Advertisement

NASH cirrhosis trials and major adverse liver outcomes: Big data needed

Published:October 31, 2022DOI:https://doi.org/10.1016/j.jhep.2022.10.022
      See Article, pages 1237–1245

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chew N.
        • Ng C.H.
        • Truong E.
        • Noureddin M.
        • Kowdley K.V.
        Non-alcoholic steatohepatitis drug development pipeline: an update.
        Semin Liver Dis. 2022 Aug; 42: 379-400
        • Setiawan V.W.
        • Stram D.O.
        • Porcel J.
        • Lu S.C.
        • Marchand L.L.
        • Noureddin M.
        Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort.
        Hepatology. 2016; 64: 1969-1977
        • Noureddin M.
        • Sanyal A.J.
        Pathogenesis of NASH: the impact of multiple pathways.
        Curr Hepatol Rep. 2018; 17: 350-360
        • Le P.
        • Payne J.Y.
        • Zhang L.
        • Deshpande A.
        • Rothberg M.B.
        • Alkhouri N.
        • et al.
        Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies.
        Clin Gastroenterol Hepatol. 2022 Aug 4;
        • Sanyal A.J.
        • Van Natta M.L.
        • Clark J.
        • Neuschwander-Tetri B.
        • Diehl A.M.
        • Dasarathy S.
        • et al.
        Prospective study of outcomes in adults with nonalcoholic fatty liver disease.
        N Engl J Med. 2021; 385: 1559-1569
        • Taylor R.S.
        • Taylor RJ
        • Bayliss S
        • Hagstrom H
        • Nasr P
        • Schattenberg JM
        • et al.
        Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
        Gastroenterology. 2020; 158: 1611-1625 e12
        • European Association for the Study of the Liver
        Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
        J Hepatol. 2018; 69: 406-460
        • Anania F.A.
        • Dimick-Santos L.
        • Mehta R.
        • Toerner J.
        • Beitz J.
        Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration.
        Hepatology. 2021; 73: 2023-2027
        • Han M.A.T.
        • Altayar O.
        • Hamdeh S.
        • Takyar V.
        • Rotman Y.
        • Etzion O.
        • et al.
        Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis.
        Clin Gastroenterol Hepatol. 2019; 17: 616-629 e26
        • Ng C.H.
        • Xiao J.
        • Lim W.H.
        • Chin Y.H.
        • Yong J.N.
        • Tan D.J.H.
        • et al.
        Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.
        Hepatology. 2022; 75: 1647-1661
        • Sanyal A.J.
        • Harrison S.A.
        • Ratziu V.
        • Abdelmalek M.F.
        • Diehl A.M.
        • Caldwell S.
        • et al.
        The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.
        Hepatology. 2019; 70: 1913-1927
        • Harrison S.A.
        • Wong V.W.
        • Okanoue T.
        • Bzowej N.
        • Vuppalanchi R.
        • Younes Z.
        • et al.
        Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials.
        J Hepatol. 2020; 73: 26-39
        • Chalasani N.
        • Abdelmalek M.F.
        • Garcia-Tsao G.
        • Vuppalanchi R.
        • Alkhouri N.
        • Rinella M.
        • et al.
        Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension.
        Gastroenterology. 2020; 158: 1334-1345 e5
        • Frenette C.
        • Kayali Z.
        • Mena E.
        • Mantry P.S.
        • Lucas K.J.
        • Neff G.
        • et al.
        Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
        J Hepatol. 2021; 74: 274-282
        • Allen A.M.
        • Therneau T.M.
        • Ahmed O.T.
        • Gidener T.
        • Mara K.C.
        • Larson J.J.
        • et al.
        Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
        J Hepatol. 2022 Nov; 77 (Epub 2022 Jul 16): 1237-1245
        • Rinella M.E.
        • Noureddin M.
        STELLAR 3 and STELLAR 4: lessons from the fall of Icarus.
        J Hepatol. 2020; 73: 9-11